Citadel Advisors
KTTA icon

Citadel Advisors’s Pasithea Therapeutics KTTA Stock Holding History

Citadel Advisors’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-56,183
Closed -$72.5K – 13644
2025
Q4 		$72.5K Sell
56,183
-11,158
-17% -$9.8K ﹤0.01% 11853
2025
Q3 		$48.5K Buy
67,341
+20,483
+44% +$15K ﹤0.01% 12227
2025
Q2 		$33.8K Buy
+46,858
New +$51.2K ﹤0.01% 11939
2023
Q2 		– Sell
-1,253
Closed -$9.75K – 14836
2023
Q1 		$9.75K Buy
+1,253
New +$14.2K ﹤0.01% 13567
2022
Q2 		– Sell
-3,647
Closed -$95K – 13543
2022
Q1 		$95K Buy
+3,647
New +$92.2K ﹤0.01% 12336

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's KTTA Position: Q1 2026 in Review

Citadel Advisors sold out of Pasithea Therapeutics (KTTA) in Q1 2026, closing a stake of 56,183 shares — an estimated $72.5K sold.

Citadel Advisors first reported a position in KTTA in Q1 2022 and held it in 5 quarters. The position peaked at $95K in Q1 2022. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Citadel Advisors reported no remaining Pasithea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 56,183 Pasithea Therapeutics shares in Q1 2026, an estimated $72.5K.
  • Citadel Advisors first reported a position in Pasithea Therapeutics in Q1 2022 and held it in 5 quarters.
  • Citadel Advisors's Pasithea Therapeutics position peaked at $95K in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.